If you have been reading about melanogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
=== November === 14 November AI-generated poetry is shown to be indistinguishable from human-written poetry and is rated more favourably. A study in the British Journal of Sports Medicine finds that over-40s could live an extra five years if they adopted the exercise routines of the top 25% of the population, while the least physically active could potentially add 11 years to their lifespan. The first direct image of what the shape of a photon would look like is created. 15 November – Measles cases are reported to have surged across the world, with an estimated 10.3 million infections in 2023, a 20% increase from 2022. 18 November – Coal ash from power plants across the United States is likely to contain up to 11 million tons of rare-earth elements – nearly eight times the amount the US has in domestic reserves – according to a study by the University of Texas at Austin. 19 November Northern and central parts of the Great Barrier Reef are reported to have suffered their worst coral bleaching on record, with up to 72 per cent mortality. Starship flight test 6 is launched. 20 November Climate change is found to have increased Atlantic hurricane wind speeds by 18 mph (29 km/h). Progress on the Human Cell Atlas is reported, with a collection of 40 new scientific papers in Nature describing the project's latest discoveries. 21 November – The first close-up image of a star outside the Milky Way is reported, using the European Southern Observatory's Very Large Telescope Interferometer.
==== Beverage ==== In 1966, the company bought a 53% controlling stake in Miller Brewing for $36 million from Lorraine Mulberger, the granddaughter of Frederick Miller, who sold the stake for religious reasons. The company sold the Miller stake in 1969 to Philip Morris for $130 million, after first cancelling an agreed-upon sale to PepsiCo for $120 million. This resulted in a lawsuit.
=== January === 1 January Figures show the annual number of migrants crossing the English Channel fell during 2023, doing so for the first time since records began. The provisional annual total for 2023 is 29,437, a 36% decrease from the 2022 total of 45,774. Secretary of State for Defence Grant Shapps says that British forces are ready to act against Houthi rebels targeting cargo ships in the Red Sea. VAT on period pants is abolished, potentially making the products cheaper to buy. A 5% increase in the price cap on domestic energy comes into force for England, Scotland and Wales. Kimberlee Singler, a 35-year-old mother accused of the murder of two of her children in Colorado, United States, appears before Westminster Magistrates Court for extradition proceedings following her arrest in London on 30 December 2023. HMRC announces a crackdown on tax evasion by those who make extra cash from "side hustle" websites like Airbnb, Amazon, eBay and Etsy. 2 January Storm Henk: The Met Office issues a severe weather warning as Storm Henk hits parts of the UK, bringing winds of up to 80 mph (128 km/h), along with the risk of flooding. A man in his 50s dies on the A433 near Kemble, Gloucestershire after a tree falls on his car during high winds. At the London Eye, strong winds blow open a pod hatch while a family of 11 is 400 ft in the air. Footage emerges of a mother and her three-year-old daughter being rescued from a submerged car in Birmingham. An 87-year-old woman dies on the B4526 near Crays Pond, Oxfordshire after the car she is driving hits a fallen tree.
Sources: en.wikipedia.org
==== Myotubular myopathy ==== Myotubular myopathy, also known as centronuclear myopathy, is recognized by pain during exercise and difficulty walking. People affected by this disease typically are wheelchair-reliant by middle adulthood, have weakness in the muscles involved in eye movement, nerve function disorders, and some form of intellectual disability. Myotubular myopathy is very rare, with less than 50 families currently affected. Genetically, myotubular myopathy can have two causes: autosomal dominant and autosomal recessive. When caused by a mutation in the DNM2 gene, the disorder is autosomal dominant, meaning it can be passed on by one mutated gene. When the mutation takes place in the BIN1 gene, the disease is instead autosomal recessive, and both genes must be mutated for the disease to be inherited. Autosomal recessive onset is most common.
Third, Article 101 of the TFEU prohibits cartels or collusive practices, including competitors engaging in (a) price fixing, (b) limiting production, (c) sharing markets, (d) applying dissimilar conditions to equivalent transactions, and (e) making contracts subject to unconnected obligations. According to Article 101(2) any such agreements between undertakings are automatically void. Article 101(3) establishes exemptions, if the collusion is for distributional or technological innovation, gives consumers a "fair share" of the benefit and does not include unreasonable restraints that risk eliminating competition anywhere. For example, in Parker ITR Srl v Commission eleven corporations that manufactured marine hoses for offshore oil rigs were fined €131 million for rigging bids and sharing markets worldwide – they would designate a "bid champion" in each case to raise prices. Secret cartels are often hard to prove, so the courts allow competition regulators to establish collusion where there is no other plausible explanation for price rises. Some agreements among businesses, however, can be highly beneficial. For instance, in a decision on the Conseil Européen de la Construction d'Appareils Domestiques, the Commission held an agreement among washing machine makers to phase out production of low-efficiency machines was lawful, especially since it would lead to "reduced pollution from electricity generation".
The soft tissue in the oral cavity is classified as either keratinized or nonkeratinized based on the presence of keratin in the epithelium. In health, the soft tissue immediately around the teeth is keratinized and is referred to as keratinized tissue or gingiva. Alveolar mucosa is non keratinized oral epithelium and is located apical to the keratinized tissue, delineated by the mucogingival junction (MGJ). It should also be pointed out that mucosa can surround a tooth in health. Nonkeratinized tissue also lines the cheeks (buccal mucosa), underside of the tongue and floor of the mouth. The lips contain both non-keratinized tissue (on the inside) and keratinized tissue on the outside, demarcated by the vermillion border. The dorsum of the tongue is keratinized and features many papillae, some of which contain taste buds. Exposure of the tooth root due to loss of keratinized tissue around the neck of a tooth is referred to as gingival recession. This can result in sensitivity or pain from the exposed tooth root surface (dentin is more permeable and soft compared to enamel and dentin is what makes up the tooth root). Recession may also cause an unasthetic appearance especially if located in the anterior dentition (front teeth). While not all cases of gingival recession require surgical correction, there are various options if that is what the patient desires. It should be reinforced that recession left untreated will not result in tooth loss, contrary to popular belief.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.